Any trial conducted after approval would be Phase
Post# of 72446
Posted On: 12/16/2016 9:00:30 PM
Any trial conducted after approval would be Phase 4, but the primary objective is usually long-term safety at the therapeutic dosage used in Phase 3, not efficacy at a different dosage. If CTIX wants to see the efficacy at dosage > 400 mg, they need to run another Phase 3.
Ziagen has 83% bioavailability. Since 300 mg of Ziagen is bioequivalent to 350 mg of Prurisol, Prurisol has 71% bioavailability. Ziagen is often prescribed for 600 mg per day, so there's:
600 mg of Ziagen * 0.83 = 498 mg of abacavir in circulation
400 mg of Prurisol * 0.71 = 284 mg of abacavir in circulation
We already know that 200 mg is working. I think 400 mg is the sweet spot for efficacy without the nasty side effects. Anything higher could have side effects similar to Ziagen.
Ziagen has 83% bioavailability. Since 300 mg of Ziagen is bioequivalent to 350 mg of Prurisol, Prurisol has 71% bioavailability. Ziagen is often prescribed for 600 mg per day, so there's:
600 mg of Ziagen * 0.83 = 498 mg of abacavir in circulation
400 mg of Prurisol * 0.71 = 284 mg of abacavir in circulation
We already know that 200 mg is working. I think 400 mg is the sweet spot for efficacy without the nasty side effects. Anything higher could have side effects similar to Ziagen.
(2)
(0)Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
